A recent meta-analysis of randomized trials in women with node-negative or node-positive operable HER2+ BC patients has shown that chemotherapy plus trastuzumab significantly reduced the absolute 10-year BC recurrence risks by 9.0% (95% CI 7.4 to 10.7; p < 0.0001) and 10-year BC mortality by 6.4% (4.9 to 7.8; p < 0.0001), compared with chemotherapy alone [10]. The gene discussed is ERBB2; the disease is breast cancer.